Arsenal Biosciences, a clinical-stage cell therapy startup noted for its substantial fundraising efforts including a $325 million Series C, has announced a reduction of 50% of its workforce. The CEO confirmed the significant staff cut as the company refocuses resources toward advancing clinical programs. This development follows earlier industry headwinds impacting cell therapy firms despite recent collaborative licensing deals with Bristol Myers Squibb.